NCT03871725 (SMART-C) is a Phase 1 clinical trial of Sonodynamic therapy (SDT) in Carotid Atherosclerosis, sponsored by First Affiliated Hospital of Harbin Medical University.

Who is sponsoring NCT03871725?

NCT03871725 is sponsored by First Affiliated Hospital of Harbin Medical University.

What drugs are being tested in NCT03871725?

Interventions in NCT03871725: Sonodynamic therapy (SDT).

What condition does NCT03871725 study?

NCT03871725 studies Carotid Atherosclerosis.

Is NCT03871725 still recruiting?

NCT03871725 is currently completed. Last updated 10 July 2024.

Last reviewed 2024-07-10 · How we verify

NCT03871725: SMART-C

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sonodynamic Therapy in the Treatment of Carotid Atherosclerosis

Completed Phase 1 Last updated 10 July 2024

What this trial tests

Phase 1 trial testing Sonodynamic therapy (SDT) in Carotid Atherosclerosis in 12 participants. Completed in 30 January 2020.

Timeline

5 January 2019

Primary endpoint
30 January 2020

30 January 2020

Quick facts

Lead sponsor	First Affiliated Hospital of Harbin Medical University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	5 January 2019
Primary completion	30 January 2020
Estimated completion	30 January 2020
Sites	1 location across China

Drugs / interventions tested

Sonodynamic therapy (SDT)

Conditions studied

Carotid Atherosclerosis — all drugs for Carotid Atherosclerosis →

Sponsor

First Affiliated Hospital of Harbin Medical University

Who can join

Adults 18 to 80, any sex, with Carotid Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sonodynamic therapy (SDT) is a new treatment for carotid atherosclerotic plaque. The purpose of this study is to evaluate the safety and initial effectiveness of this technique.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives.
Shah N, Squire J, Guirguis M, Saha D, et al · · 2022 · cited 12× · PMID 35454910 · DOI 10.3390/cancers14082004
Sonodynamic therapy reduces iron retention of hemorrhagic plaque.
Li B, Gong J, Sheng S, Lu M, et al · · 2021 · cited 10× · PMID 33532592 · DOI 10.1002/btm2.10193
Sonodynamic therapy for the treatment of atherosclerosis.
Zhang Y, Yang Y, Feng Y, Gao X, et al · · 2024 · cited 9× · PMID 38799235 · DOI 10.1016/j.jpha.2023.11.016
Nanosensitizer-assisted sonodynamic therapy for breast cancer.
Yu J, Hu JR, Tian Y, Lei YM, et al · · 2025 · cited 8× · PMID 40197318 · DOI 10.1186/s12951-025-03311-3
Ultrasound-driven atherosclerosis nanomedicine: from mechanical, cavitation, and sonodynamic therapies to bedside translation.
Shao Y, Luo J, Tu S, Xie Y, et al · · 2025 · cited 1× · PMID 41351120 · DOI 10.1186/s12951-025-03857-2
Ultrasound-activatable transition metal complexes to potentiate sonodynamic therapy.
Lee LC, Lo KK. · · 2025 · cited 1× · PMID 41257199 · DOI 10.1039/d5sc06387f
[Utilizing Sonodynamic Therapy-Induced Pyroptosis for Liver Cancer Therapy].
Zhang N, Dai Z. · · 2024 · PMID 39507962 · DOI 10.12182/20240960210

Verify or expand the search:

Other trials of Sonodynamic therapy (SDT)

Trials testing the same drug.

NCT03382249 — Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With Carotid Atherosclerotic Plaques · Phase 1, PHASE2 · withdrawn

Other recruiting trials for Carotid Atherosclerosis

Currently open trials in the same condition.

NCT07298655 — 3D Contrast Enhanced Microvascular Ultrasound of Carotid Atherosclerosis for the Detection of Carotid Plaque Neo-Revascu · NA · recruiting
NCT06590012 — Evaluating the Impact of 'Tertinat' on Patients with Atherosclerosis-Related Cardiovascular Diseases · Phase 2 · recruiting
NCT06528717 — The Role of Maintaining External Carotid Artery Flow in Graft Interposition After Carotid Endarterectomy · recruiting
NCT06541691 — Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic · NA · recruiting
NCT06253962 — Carotid Atherosclerosis in Predicting Coronary Artery Disease · recruiting

Other First Affiliated Hospital of Harbin Medical University trials

Trials by the same sponsor.

NCT07020195 — QFR-Based Functional SYNTAX Score System in Optimizing Revascularization Strategy for Multivessel Disease · NA · not yet recruiting
NCT06975592 — Study on the Mechanism of Multi-group Analysis of the Influence of Depression on Common Cardiovascular Diseases · not yet recruiting
NCT06995456 — Multivariate Analysis and Prediction of Hypertensive Disorder Complicating Pregnancy and Its Related Mechanism · not yet recruiting
NCT07087093 — Effects of Ketone Esters on Circulating Senescent T Lymphocytes (T Cells) and Inflammation Levels in the Elderly · NA · recruiting
NCT06565845 — Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03871725 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Harbin Medical University
Last refreshed: 10 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03871725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing